Ask AI
ProCE Banner Activity

FAQs Regarding Later-Generation TKIs for Frontline Treatment of Chronic-Phase CML

Clinical Thought

Read expert-answered FAQs about using later-generation TKIs for the frontline treatment of chronic-phase CML and learn how hematology/oncology pharmacists can help personalize and improve patient care.

Released: June 23, 2025

Expiration: December 22, 2025

Continue Activity View Activity

Share

Provided by

Provided by ProCE LLC. in partnership with Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Partners

Clinical Care Options, LLC

ProCE Banner

Disclosure

Primary Author

Karen M. Fancher, PharmD, BCOP: consultant/advisor/speaker: AstraZeneca.

Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP: consultant/advisor/speaker: Genentech, Genmab, GlaxoSmithKline, Incyte, Sanofi.

Anthony J. Perissinotti, PharmD, BCOP: consultant/advisor/speaker: AbbVie, Amgen, Servier, Syndax.